^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:Byvasda (bevacizumab biosimilar) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Innovent Biologics Press Release
    Title:

    Innovent Announces the NMPA Granted New Indication Approval for BYVASDA (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

    Published date:
    12/28/2020
    Excerpt:
    Innovent Biologics, Inc. (Innovent)...today announces that BYVASDA (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult recurrent glioblastoma...